Search research articles
Contact Us
Filters
Showing results (1-10 of 21) with videos related to
Page
of 3
Sort By:
The Journal of Biological Chemistry
|
May 26, 2019
Increased 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 activity in response to EGFR signaling contributes to non-small cell lung cancer cell survival
Nadiia Lypova, Sucheta Telang, Jason Chesney, et al.
Cells
|
August 7, 2021
PFKFB3 Inhibition Impairs Erlotinib-Induced Autophagy in NSCLCs
Nadiia Lypova, Susan M Dougherty, Lilibeth Lanceta, et al.
Oncotarget
|
August 14, 2014
Fructose-2,6-bisphosphate synthesis by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 (PFKFB4) is required for the glycolytic response to hypoxia and tumor growth
Jason Chesney, Jennifer Clark, Alden C Klarer, et al.
Breast Cancer Research and Treatment
|
February 18, 2021
Differential gene expression analysis of palbociclib-resistant TNBC via RNA-seq
Lilibeth Lanceta, Nadiia Lypova, Conor O'Neill, et al.
Melanoma Research
|
March 22, 2018
Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors
Jason Chesney, Yoannis Imbert-Fernandez, Sucheta Telang, et al.
Experimental Eye Research
|
August 23, 2011
MUC1/A and MUC1/B splice variants differentially regulate inflammatory cytokine expression
Yoannis Imbert-Fernandez, Brandie N Radde, Yun Teng, et al.
Breast Cancer Research and Treatment
|
September 11, 2016
Inhibition of 6-phosphofructo-2-kinase (PFKFB3) suppresses glucose metabolism and the growth of HER2+ breast cancer
Julie O'Neal, Amy Clem, Lindsey Reynolds, et al.
Endocrine-Related Cancer
|
November 26, 2025
Targeting METTL3 induces a metabolic vulnerability in ER+ breast carcinoma cells
Mary H Sumlut, Jing Feng, Xiang Zhang, et al.
Cancers
|
July 13, 2024
Genomic Deletion of PFKFB3 Decreases In Vivo Tumorigenesis
Yoannis Imbert-Fernandez, Simone M Chang, Lilibeth Lanceta, et al.
Molecular Cancer Therapeutics
|
August 25, 2011
Targeting the intracellular MUC1 C-terminal domain inhibits proliferation and estrogen receptor transcriptional activity in lung adenocarcinoma cells
Carolyn M Klinge, Brandie N Radde, Yoannis Imbert-Fernandez, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 21) with videos related to
Sort By:
Page
of 3
The Journal of Biological Chemistry
|
May 26, 2019
Increased 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 activity in response to EGFR signaling contributes to non-small cell lung cancer cell survival
Nadiia Lypova, Sucheta Telang, Jason Chesney, et al.
Cells
|
August 7, 2021
PFKFB3 Inhibition Impairs Erlotinib-Induced Autophagy in NSCLCs
Nadiia Lypova, Susan M Dougherty, Lilibeth Lanceta, et al.
Oncotarget
|
August 14, 2014
Fructose-2,6-bisphosphate synthesis by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 (PFKFB4) is required for the glycolytic response to hypoxia and tumor growth
Jason Chesney, Jennifer Clark, Alden C Klarer, et al.
Breast Cancer Research and Treatment
|
February 18, 2021
Differential gene expression analysis of palbociclib-resistant TNBC via RNA-seq
Lilibeth Lanceta, Nadiia Lypova, Conor O'Neill, et al.
Melanoma Research
|
March 22, 2018
Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors
Jason Chesney, Yoannis Imbert-Fernandez, Sucheta Telang, et al.
Experimental Eye Research
|
August 23, 2011
MUC1/A and MUC1/B splice variants differentially regulate inflammatory cytokine expression
Yoannis Imbert-Fernandez, Brandie N Radde, Yun Teng, et al.
Breast Cancer Research and Treatment
|
September 11, 2016
Inhibition of 6-phosphofructo-2-kinase (PFKFB3) suppresses glucose metabolism and the growth of HER2+ breast cancer
Julie O'Neal, Amy Clem, Lindsey Reynolds, et al.
Endocrine-Related Cancer
|
November 26, 2025
Targeting METTL3 induces a metabolic vulnerability in ER+ breast carcinoma cells
Mary H Sumlut, Jing Feng, Xiang Zhang, et al.
Cancers
|
July 13, 2024
Genomic Deletion of PFKFB3 Decreases In Vivo Tumorigenesis
Yoannis Imbert-Fernandez, Simone M Chang, Lilibeth Lanceta, et al.
Molecular Cancer Therapeutics
|
August 25, 2011
Targeting the intracellular MUC1 C-terminal domain inhibits proliferation and estrogen receptor transcriptional activity in lung adenocarcinoma cells
Carolyn M Klinge, Brandie N Radde, Yoannis Imbert-Fernandez, et al.
Page
of 3